

The expression of OX40/OX40L in atopic dermatitis.

Published: 09-10-2017

Last updated: 12-04-2024

The aim of the project is to gain more insight of the OX40/OX40L expression patterns in atopic dermatitis. This information can be used to adapt the design of subsequent in vitro/ in vivo research, clinical research, but also the development of the...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Epidermal and dermal conditions
Study type	Observational invasive

Summary

ID

NL-OMON46788

Source

ToetsingOnline

Brief title

OX40/OX40L in atopische dermatitis

Condition

- Epidermal and dermal conditions

Synonym

Atopic Dermatitis

Research involving

Human

Sponsors and support

Primary sponsor: Derphartox

Source(s) of monetary or material Support: Farmaceutische industrie

Intervention

Keyword: Atopic Dermatitis, Human, OX40/OX40L

Outcome measures

Primary outcome

OX40/OX40L expression

Secondary outcome

-

Study description

Background summary

Atopic dermatitis is an immune-mediated disease in which proinflammatory protein mediators, released by skin cells/infiltrating cells, and a defect in the stratum corneum are intrinsic to the characteristics of the disease. It may be possible to treat atopic dermatitis using drugs aimed at preventing the synthesis of such mediators.

Study objective

The aim of the project is to gain more insight of the OX40/OX40L expression patterns in atopic dermatitis. This information can be used to adapt the design of subsequent in vitro/ in vivo research, clinical research, but also the development of the medicine targeted to OX40/OX40L.

Study design

Lesional and non-lesional skin biopsies of 3 mm in diameter and blood from volunteers with atopic dermatitis will be investigated for differences in OX40/OX40L expression.

Study burden and risks

The health risks associated with taking skin biopsies are small. It is possible to obtain a slight scar formation and/or discolouration at the site of the biopsy punch.

Contacts

Public

Derphartox

Wytemaweg 80
Rotterdam 3015 CN
NL

Scientific

Derphartox

Wytemaweg 80
Rotterdam 3015 CN
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Patients with moderate to severe atopische dermatitis

Exclusion criteria

Volunteers undergoing UV/light therapy or taking systemic drugs such as cyclosporin A or methotrexate

Volunteers using local topical corticosteroids

Volunteers developing Köbner phenomenon at wound sites

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 05-03-2018

Enrollment: 60

Type: Actual

Ethics review

Approved WMO

Date: 09-10-2017

Application type: First submission

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Approved WMO

Date: 19-04-2018

Application type: Amendment

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Approved WMO

Date: 31-10-2018

Application type: Amendment

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL63401.098.17